Unlocking the power of real-world data – New podcast episode

Research / 31 March 2023

Real-world data is a rich source of evidence for pharmacovigilance, but there are challenges yet to be faced before unlocking its true potential as a resource.

Real-world data, or observational data collected during routine clinical care, could be a valuable source of evidence in pharmacovigilance. However, there are still hurdles to overcome before it can deliver on that value.

In the latest episode of the Drug Safety Matters podcast, Federica Santoro and Patrick Ryan from Johnson & Johnson discuss the challenges of using real-world data for patient safety and how this resource may be harnessed for pharmacovigilance through some ‘proof of concept’ projects such as OHDSI and EHDEN.

Like what you hear? Then subscribe to the podcast by visiting the Drug Safety Matters website.

You may also like

The colour of signals

Herbal remedies have been used for thousands of years to treat what ails us. Yet why do we still know so little about their potential side effects compared to modern medicines?

Research / 29 August 2023

Digging deeper into Montelukast and nightmares

There is much to be gained from using VigiBase to further explore known adverse reactions to drugs, as some may be having more of an impact on patients than first thought.

Research / 18 September 2023

Assessing safety in clinical trials - New podcast out now

Medicine safety monitoring applies to all aspects of drug development, but how much is it impacted by patient diversity and study type in clinical trials?

Research / 29 June 2023

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more